InnoQuant slide scanner: new publication
μPharma: A microfluidic, AI-driven pharmacotyping platform for single-cell drug sensitivity prediction in leukemia
In a recent study published in the Med journal, Hu et al. have developed a microfluidic AI platform dedicated to single-cell prediction of of leukemia drug sensitivity without direct drug exposure.
By leveraging pretreatment biomarkers, μPharma provides accurate, automated, and same-day therapeutic insights, facilitating treatment selection and revealing intratumor heterogeneity, thus advancing precision oncology toward broader clinical adoption.
The InnoQuant slide scanner was used to capture protein staining signals from Actin, LCK, pLCK, and BCL2 using four lasers and five emission filters. Except for AF647 (LCK) and APC-Cy7 (pBCL2), all fluorophores used distinct lasers, optical paths, filters, and PMTs; thus, spectral bleed-through was expected to be minimal by design.
The study validates pBCL2 and pLCK as biomarkers for venetoclax and dasatinib sensitivity and μPharma enables clinically feasible same-day precision cancer treatment decisions.
Keywords:
- Drug prediction
- Leukemia
- InnoQuant
Original publication: Access the publication